Protein Kinase Inhibitors: all 15,278 studies that test it

Page 53 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic ArthritisCompletedNCT01519089Phase 3Results posted
• Phase II Study of Alternating Sunitinib and TemsirolimusCompletedNCT01517243Phase 2Results posted
• Sirolimus Injections for Autoimmune ScleritisCompletedNCT01517074Phase 1/2Results posted
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaCompletedNCT01515176Phase 1/2Results posted
• Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationTerminatedNCT01514864Phase 2Results posted
• Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibCompletedNCT01514448Phase 4Results posted
• Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)CompletedNCT01513902Phase 1Results posted
• A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasCompletedNCT01512758Phase 1Results posted
• Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric CancerCompletedNCT01512745Phase 3Results posted
• BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced MelanomaCompletedNCT01512251Phase 1/2Results posted
• Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01510756Phase 2Results posted
• Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) PatientsTerminatedNCT01508117Phase 2Results posted
• Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic LiposarcomaCompletedNCT01506596Phase 2Results posted
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid CancerCompletedNCT01502410Phase 2Results posted
• PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell CarcinomaTerminatedNCT01502228Not applicableResults posted
• PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT01500733Phase 2Results posted
• Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic ArthritisCompletedNCT01500551Phase 2/3Results posted
• Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood CancerCompletedNCT01499303Phase 2Results posted
• Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast CancerTerminatedNCT01499160Phase 2Results posted
• Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)TerminatedNCT01499043Phase 2Results posted
• Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast CancerCompletedNCT01498458Phase 1Results posted
• An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)TerminatedNCT01498445Phase 1/2Results posted
• To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompletedNCT01496313Phase 4Results posted
• Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaTerminatedNCT01495988Phase 2Results posted
• HKI-272 for HER2-Positive Breast Cancer and Brain MetastasesCompletedNCT01494662Phase 2Results posted
• INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.CompletedNCT01493414Phase 3Results posted
• Everolimus as Second-line Therapy in Metastatic Renal Cell CarcinomaCompletedNCT01491672Phase 2Results posted
• Dasatinib in Advanced Squamous Cell Lung CancerTerminatedNCT01491633Phase 2Results posted
• A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)CompletedNCT01490866Phase 2Results posted
• A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisCompletedNCT01490632Phase 2Results posted
• Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT01488487Phase 2Results posted
• Cetuximab and Dasatinib in Recurrent Squamous Cell CarcinomaTerminatedNCT01488318Phase 2Results posted
• Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibCompletedNCT01487265Phase 2Results posted
• Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel ChemotherapyCompletedNCT01485861Phase 1/2Results posted
• Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerTerminatedNCT01484041Phase 1/2Results posted
• Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaCompletedNCT01482962Phase 3Results posted
• Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT01481129Phase 2Results posted
• A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line TherapyCompletedNCT01478594Phase 2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT01478581Phase 2Results posted
• Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to ImatinibCompletedNCT01478373Phase 2Results posted
• Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K MutationTerminatedNCT01474551Phase 2Results posted
• Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) ToxicityTerminatedNCT01473732Not applicableResults posted
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results posted
• Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal CancerCompletedNCT01471353Phase 2Results posted
• Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast CancerCompletedNCT01471106Phase 2Results posted
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative ColitisCompletedNCT01470612Phase 3Results posted
• A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's DiseaseCompletedNCT01470599Phase 2Results posted
• Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck CancerCompletedNCT01469546Phase 2Results posted
• First In Human, Phase 1 Study of AG013736 In Patients With Solid TumorsCompletedNCT01469052Phase 1Results posted
• Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate TherapyCompletedNCT01469013Phase 2Results posted
• Pazopanib and ARQ 197 for Advanced Solid TumorsCompletedNCT01468922Phase 1Results posted
• Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerCompletedNCT01468909Phase 2Results posted
• Reversing Hormone Resistance in Advanced Breast Cancer With PazopanibCompletedNCT01466972Phase 2Results posted
• Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaCompletedNCT01466881Phase 2Results posted
• LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the LungCompletedNCT01466660Phase 2Results posted
• Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsCompletedNCT01466036Phase 2Results posted
• Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PROCompletedNCT01465802Phase 2Results posted
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01465763Phase 3Results posted
• Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By SurgeryCompletedNCT01465659Phase 1/2Results posted
• Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular CarcinomaTerminatedNCT01465464Phase 3Results posted
• A Study of LY3007113 in Participants With Advanced CancerCompletedNCT01463631Phase 1Results posted
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or EpendymomaCompletedNCT01462695Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced AngiosarcomaCompletedNCT01462630Phase 2Results posted
• Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01460160Phase 2Results posted
• A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01458951Phase 3Results posted
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisCompletedNCT01458574Phase 3Results posted
• Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal CancerTerminatedNCT01457846Phase 2Results posted
• BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)TerminatedNCT01453595Phase 1/2Results posted
• MSC2015103B in Solid TumorsTerminatedNCT01453387Phase 1Results posted
• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and SirolimusTerminatedNCT01453140Phase 1/2Results posted
• Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic MemoryCompletedNCT01449955Not applicableResults posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)CompletedNCT01449461Phase 1/2Results posted
• Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced CancerCompletedNCT01449370Phase 1Results posted
• Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedNCT01447914Phase 2Results posted
• Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue SarcomaCompletedNCT01446809Not applicableResults posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Sirolimus for Advanced Age-Related Macular DegenerationCompletedNCT01445548Phase 1/2Results posted
• Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT01445080Phase 1/2Results posted
• Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast CancerCompletedNCT01441947Phase 2Results posted
• Dasatinib in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT01441882Phase 2Results posted
• Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain MetastasesCompletedNCT01441596Phase 2Results posted
• Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258CompletedNCT01440959Phase 2Results posted
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisTerminatedNCT01437787Phase 3Results posted
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant MelanomaCompletedNCT01436656Phase 1Results posted
• Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau SyndromeCompletedNCT01436227Phase 2Results posted
• SB1518 for Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01436084Phase 2Results posted
• A Study of Axitinib in Advanced Carcinoid TumorsCompletedNCT01435122Phase 2Results posted
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasCompletedNCT01434602Phase 1/2Results posted
• A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)TerminatedNCT01433991Phase 1/2Results posted
• A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or LymphomaCompletedNCT01432951Phase 1Results posted
• A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)TerminatedNCT01431534Phase 1Results posted
• Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell TransplantCompletedNCT01431209Phase 2Results posted
• Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast CancerTerminatedNCT01430585Phase 2Results posted
• Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to BoneTerminatedNCT01428219Phase 2Results posted
• Investigation of Ritonavir Effects on Afatinib Exposure in Healthy SubjectsCompletedNCT01426958Phase 1Results posted
• MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by SurgeryCompletedNCT01425879Phase 2Results posted
• Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic MelanomaCompletedNCT01425008Phase 1Results posted
• Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFCompletedNCT01423851Phase 1/2Results posted
• Study of Ruxolitinib in Pancreatic Cancer PatientsCompletedNCT01423604Phase 2Results posted
• A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerTerminatedNCT01420081Phase 2Results posted

← Protein Kinase Inhibitors overview